Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, randomized, clinical study with a single subcutaneous dose to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of two Regular recombinant human insulins, the test drug being the Regular Human Insulin produced by Bioton SA and the reference medicine Humulin® R produced by Eli Lilly Brasil Ltda using euglycemic and hyperinsulinemic clamp technique in type 1 diabetic research participants (PPES005/17)

Trial Profile

A double-blind, randomized, clinical study with a single subcutaneous dose to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of two Regular recombinant human insulins, the test drug being the Regular Human Insulin produced by Bioton SA and the reference medicine Humulin® R produced by Eli Lilly Brasil Ltda using euglycemic and hyperinsulinemic clamp technique in type 1 diabetic research participants (PPES005/17)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2018

At a glance

  • Drugs Insulin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 20 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top